A new era in cancer therapeutics?
Highlights from the 14th EORTC-NCI-AACR Symposium Molecular Targets and Cancer Therapeutics, 19-22 November 2002, in Frankfurt, Germany.
Westwell
Andrew D
AD
School of Pharmaceutical Sciences, University of Nottingham, University Park, Nottingham, UK NG7 2RD. Andrew.Westwell@nottingham.ac.uk
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006801:Humans; D000068877:Imatinib Mesylate; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000517:prevention & control; D010597:Pharmacogenetics / Q000639:trends*; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D001549:Benzamides; D004791:Enzyme Inhibitors; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate